Luis V Syro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9170469/publications.pdf Version: 2024-02-01



Luis V Svpo

#	Article	IF	CITATIONS
1	From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocrine-Related Cancer, 2017, 24, C5-C8.	1.6	262
2	Aggressive pituitary adenomas—diagnosis and emerging treatments. Nature Reviews Endocrinology, 2014, 10, 423-435.	4.3	239
3	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	1.9	196
4	Anti-VEGF therapy in pituitary carcinoma. Pituitary, 2012, 15, 445-449.	1.6	115
5	Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Research, 2009, 29, 3759-68.	0.5	101
6	MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathologica, 2008, 115, 261-262.	3.9	100
7	Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Human Pathology, 2007, 38, 185-189.	1.1	96
8	Treatment of pituitary neoplasms with temozolomide. Cancer, 2011, 117, 454-462.	2.0	94
9	Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clinical Endocrinology, 2006, 65, 552-553.	1.2	90
10	Clinical Biology of the Pituitary Adenoma. Endocrine Reviews, 2022, 43, 1003-1037.	8.9	81
11	Autophagy in the endocrine glands. Journal of Molecular Endocrinology, 2014, 52, R151-R163.	1.1	76
12	Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. Pituitary, 2016, 19, 345-355.	1.6	72
13	Invasive, Atypical and Aggressive Pituitary Adenomas and Carcinomas. Endocrinology and Metabolism Clinics of North America, 2015, 44, 99-104.	1.2	59
14	MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary, 2010, 13, 367-379.	1.6	51
15	Progress in the Diagnosis and Classification of Pituitary Adenomas. Frontiers in Endocrinology, 2015, 6, 97.	1.5	51
16	Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective. Pituitary, 2020, 23, 327-337.	1.6	49
17	MicroRNAs in the Human Pituitary. Endocrine Pathology, 2011, 22, 134-143.	5.2	48
18	Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. Frontiers in Endocrinology, 2018, 9, 318.	1.5	47

LUIS V SYRO

#	Article	IF	CITATIONS
19	Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy. Hormones, 2011, 10, 162-167.	0.9	45
20	Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics, 2012, 67, 119-123.	0.6	42
21	Crooke's Cell Tumors of the Pituitary. Neurosurgery, 2015, 76, 616-622.	0.6	38
22	Biomarkers of pituitary neoplasms. Anticancer Research, 2012, 32, 4639-54.	0.5	38
23	Pituitary tumors in patients with MEN1 syndrome. Clinics, 2012, 67, 43-48.	0.6	37
24	Pituitary pathology in traumatic brain injury: a review. Pituitary, 2019, 22, 201-211.	1.6	36
25	Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary, 2017, 20, 84-92.	1.6	34
26	O-6-Methylguanine-DNA Methyltransferase (MGMT) Immunohistochemical Expression in Pituitary Corticotroph Adenomas. Neurosurgery, 2012, 70, 491-496.	0.6	33
27	Stem Cells and Cancer Stem-Like Cells in Endocrine Tissues. Endocrine Pathology, 2013, 24, 1-10.	5.2	31
28	Autophagy in endocrine tumors. Endocrine-Related Cancer, 2015, 22, R205-R218.	1.6	31
29	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
30	DICER1 gene mutations in endocrine tumors. Endocrine-Related Cancer, 2018, 25, R197-R208.	1.6	29
31	Collision Tumors of the Sella: Craniopharyngioma and Silent Pituitary Adenoma Subtype 3: Case Report. Endocrine Pathology, 2009, 20, 50-55.	5.2	25
32	Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones, 2009, 8, 303-306.	0.9	24
33	Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society―survey. Pituitary, 2019, 22, 37-45.	1.6	24
34	Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection. Pituitary, 2021, 24, 839-853.	1.6	24
35	Current status on histological classification in Cushing's disease. Pituitary, 2015, 18, 217-224.	1.6	19
36	Low Immunohistochemical Expression of MGMT in ACTH Secreting Pituitary Tumors of Patients with Nelson Syndrome. Endocrine Pathology, 2010, 21, 227-229.	5.2	18

3

Luis V Syro

#	Article	IF	CITATIONS
37	65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update. Endocrine-Related Cancer, 2018, 25, T159-T169.	1.6	18
38	Plurihormonality in Pituitary Adenomas Associated with Acromegaly. Endocrine Pathology, 2006, 17, 291-296.	5.2	13
39	Melanoma of the sellar region mimicking pituitary adenoma. Neuropathology, 2013, 33, 175-178.	0.7	13
40	Letter to the Editor. Endocrine Pathology, 2015, 26, 93-94.	5.2	13
41	Inflammatory pseudotumor of the pituitary: Case report. World Neurosurgery, 2004, 62, 264-267.	1.3	12
42	Ghrelin immunoexpression in pituitary adenomas. Pituitary, 2011, 14, 318-322.	1.6	12
43	Necrotizing Granulomatous Hypophysitis Presenting as a Sellar Mass. Endocrine Pathology, 2011, 22, 6-9.	5.2	10
44	Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. Pituitary, 2012, 15, 342-349.	1.6	10
45	Non-uniform Response to Temozolomide Therapy in a Pituitary Gonadotroph Adenoma. Canadian Journal of Neurological Sciences, 2012, 39, 683-685.	0.3	9
46	Improving differential diagnosis of pituitary adenomas. Expert Review of Endocrinology and Metabolism, 2014, 9, 377-386.	1.2	9
47	Prolactin-Producing Pituitary Adenoma Associated with Prolactin Cell Hyperplasia. Endocrine Pathology, 2002, 13, 157-166.	5.2	8
48	Immunoglobulin G4 (IgG4)-Related Hypophysitis. Endocrine Pathology, 2017, 28, 308-314.	5.2	8
49	Selective molecular biomarkers to predict biologic behavior in pituitary tumors. Expert Review of Endocrinology and Metabolism, 2017, 12, 177-185.	1.2	8
50	Pituitary stem cells: candidates and implications. Pituitary, 2013, 16, 413-418.	1.6	7
51	Treatment of Invasive Silent Somatotroph Pituitary Adenoma with Temozolomide. Report of a Case and Review of the Literature. Endocrine Pathology, 2015, 26, 135-139.	5.2	7
52	Pituitary Adenoma with Peliosis: A Report of Two Cases. Endocrine Pathology, 2009, 20, 41-45.	5.2	6
53	Neurocysticercosis, Meningioma, and Silent Corticotroph Pituitary Adenoma in a 61-Year-Old Woman. Case Reports in Pathology, 2012, 2012, 1-5.	0.2	6
54	Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas: a Histologic Study. Pathology and Oncology Research, 2017, 23, 803-809.	0.9	6

LUIS V SYRO

#	Article	IF	CITATIONS
55	Undifferentiated Sarcoma of the Sellar Region. Endocrine Pathology, 2011, 22, 159-164.	5.2	5
56	Ghrelin Immunoexpression in the Human Hypophysis. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 77-81.	0.6	5
57	Prolactinomas: diagnosis and treatment. Expert Review of Endocrinology and Metabolism, 2012, 7, 233-241.	1.2	5
58	Necrotizing Infundibuloneurohypophysitis: Case Report and Literature Review. Endocrine Pathology, 2012, 23, 205-211.	5.2	5
59	Human Kallikrein 10 Expression in Surgically Removed Human Pituitary Corticotroph Adenomas. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 433-437.	0.6	5
60	Tumefactive Postmenopausal Gonadotroph Cell Hyperplasia. Endocrine Pathology, 2012, 23, 108-111.	5.2	4
61	Clinicopathologic features of familial pituitary adenomas. Diagnostic Histopathology, 2016, 22, 85-91.	0.2	4
62	Pituitary immunoexpression of ghrelin in anorexia nervosa. Pituitary, 2012, 15, 533-538.	1.6	3
63	Human kallikrein 10 in surgically removed human pituitary adenomas. Hormones, 2014, 14, 272-9.	0.9	3
64	Nonpituitary Sellar Masses. , 2017, , 631-641.		3
65	Alpha subunit in clinically non-functioning pituitary adenomas: An immunohistochemical study. Pathology Research and Practice, 2017, 213, 1130-1133.	1.0	3
66	Microvessel density and VEGF expression in pituitaries of pregnant women. Hormones, 2013, 12, 292-297.	0.9	2
67	Biomarkers of pituitary carcinomas. Expert Review of Endocrinology and Metabolism, 2016, 11, 253-261.	1.2	2
68	Reply to treatment of pituitary neoplasms with temozolomide. Cancer, 2011, 117, 4102-4102.	2.0	1
69	Biomarkers of acromegaly. Endocrine, 2015, 49, 4-5.	1.1	1
70	Overproduction of Hormones by Pituitary Tumors. , 2020, , 655-665.		1
71	Ghrelin: A GH-Releasing, Appetite-Regulating Gastric Hormone. Advances in Neuroimmune Biology, 2013, 4, 51-65.	0.7	0
72	Ghrelin Immunexpression in Pituitary Adenomas. FASEB Journal, 2011, 25, 1001.13.	0.2	0

Luis V Syro

#	Article	IF	CITATIONS
73	Immunohistochemical Demonstration of Ghrelin in the Nontumorous Human Hypophysis. FASEB Journal, 2011, 25, 1002.5.	0.2	0
74	Treatment of Aggressive Pituitary Adenomas and Carcinomas – An Overview. European Neurological Review, 2012, 7, 178.	0.5	0
75	Treatment of Aggressive Pituitary Adenomas and Carcinomas—An Overview. US Endocrinology, 2012, 08, 50.	0.3	0
76	VEGF immunoexpression in the pituitaries of pregnant women. FASEB Journal, 2012, 26, 48.1.	0.2	0
77	Increased microvessel density in the pituitarires of pregnant women. FASEB Journal, 2012, 26, 832.12.	0.2	0
78	Autophagy in pituitary tumors. FASEB Journal, 2013, 27, 1086.6.	0.2	0